Published online 11 July 2005
Methods Online |
A novel high-throughput (HTP) cloning strategy for site-directed designed chimeragenesis and mutation using the Gateway cloning system
Primer Production Department, Invitrogen Corporation, Yokohama Kanazawa High-Tech Center Techno-Core Building.4F 1-1-1 Fukuura, Kanazawa, Yokohama, Kanagawa, 236-0004 Japan 1Research and Development Department, Invitrogen Corporation, Yokohama Kanazawa High-Tech Center Techno-Core Building.4F 1-1-1 Fukuura, Kanazawa, Yokohama, Kanagawa, 236-0004 Japan 2Service Laboratory Department, Invitrogen Corporation, Yokohama Kanazawa High-Tech Center Techno-Core Building.4F 1-1-1 Fukuura, Kanazawa, Yokohama, Kanagawa, 236-0004 Japan 3Japan Biological Information Consortium Grande Building5F, 2-26-9 Hacchoubori Chuoh Tokyo, 104-0032, Japan 4Center for Medical Genomics, National Cancer Center Research Institute 5-1-1 Tsukiji Chuoh, Tokyo, 104-0045, Japan
*To whom correspondence should be addressed. Email: shigeo.tanaka{at}invitrogen.com
Received April 27, 2005. Revised June 10, 2005. Accepted June 10, 2005.
There is an increasing demand for easy, high-throughput (HTP) methods for protein engineering to support advances in the development of structural biology, bioinformatics and drug design. Here, we describe an N- and C-terminal cloning method utilizing Gateway cloning technology that we have adopted for chimeric and mutant genes production as well as domain shuffling. This method involves only three steps: PCR, in vitro recombination and transformation. All three processes consist of simple handling, mixing and incubation steps. We have characterized this novel HTP method on 96 targets with >90% success. Here, we also discuss an N- and C-terminal cloning method for domain shuffling and a combination of mutation and chimeragenesis with two types of plasmid vectors.